Home » Posts tagged with » Phase 2 ADVISE study
Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis

Arena begins ADVISE clinical trial for etrasimod in atopic dermatitis

Arena Pharmaceuticals has dosed the first subject in the phase 2 ADVISE clinical trial, which is evaluating etrasimod for the treatment of moderate-to-severe atopic dermatitis (AD). Etrasimod is a once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator. Atopic dermatitis is considered to be a serious, chronic immune-mediated disease in which symptoms are varied. However, the usual […]